RxDoctor Payments Data

Karolina Cichocka

Family · Farmington, CTNPI 1104261122

Payments from drug & device makers

$2,706in general payments, 2019–2025

Across 109 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • SPR Therapeutics, Inc$366
  • Collegium Pharmaceutical, Inc.$238
  • Teva Pharmaceuticals USA, Inc.$210
  • Pfizer$144
  • Saluda Medical Americas, Inc.$139
  • plus $906 from 20 others

What the payments were for

  • Food & beverage$2,694100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,706 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$127,441
Medicare patients
170
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl329$310,406
Xtampza ErOxycodone Myristate238$301,218
Nucynta ErTapentadol Hcl43$54,488
Oxycodone Hcl1,365$36,428
Morphine Sulfate ErMorphine Sulfate712$36,051
LinzessLinaclotide43$31,888
Nurtec OdtRimegepant Sulfate26$31,598
NucyntaTapentadol Hcl24$25,010
UbrelvyUbrogepant20$23,534
Fentanyl165$22,645
Aimovig AutoinjectorErenumab-Aooe26$19,506
Oxymorphone Hcl ErOxymorphone Hcl32$18,127
HorizantGabapentin Enacarbil17$17,996
Hydromorphone ErHydromorphone Hcl44$17,871
Ajovy AutoinjectorFremanezumab-Vfrm15$16,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Nucynta, Belbuca$238$393,220319 claims
AbbVieLinzess, Ubrelvy$702$55,42263 claims
PfizerNurtec Odt$144$31,59826 claims
Arbor Pharmaceuticals, Inc.Horizant$28$17,99617 claims
Redhill Biopharma Inc.Movantik$14$11,00917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →